Phaseline

Companies › Incyclix Bio

Incyclix Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
INX-315
CDK2 inhibitor
CDK2Phase 1Breast CancerJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05735080INX-315Phase 1Breast CancerOncologyJul 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CDK2 (1)

Companies with the same targets

NiKang Therapeutics Avenzo Therapeutics Chia Tai Tianqing Pharmaceutical Group BeiGene AstraZeneca Eilean Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.